logo

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 10989720 B1

PDFFull Text
Date of Patent:
Apr. 27, 2021

Filed:

Apr. 30, 2016

Method for clinically and pathologically monitoring alzheimer's disease through concentration of amyloidbeta in plasma

Applicant:

Seoul National University R&db Foundation, Seoul, KR;

Inventors:

Inhee Mook, Seoul, KR;

Jong-Chan Park, Seoul, KR;

Hyun Jin Cho, Suwon-si, KR;

Sun-Ho Han, Seoul, KR;

Assignee:

Seoul National University R&DB Foundation, Seoul, KR;

Attorneys:

Vorys, Sater, Seymour & Pease LLP

Muh Suhn Koh

Primary Examiner:

Russell S Negin

Int. Cl.
CPC ...
G01N 33/48 (2006.01); G01N 33/50 (2006.01); G01N 33/68 (2006.01); G01N 1/10 (2006.01); C07K 14/81 (2006.01); G01N 1/30 (2006.01); G16H 50/20 (2018.01); G16H 50/30 (2018.01); A61B 5/15 (2006.01); G16H 10/40 (2018.01); C07K 14/47 (2006.01);
U.S. Cl.
CPC ...
G01N 33/6896 (2013.01); A61B 5/15 (2013.01); C07K 14/4711 (2013.01); C07K 14/81 (2013.01); G01N 1/10 (2013.01); G01N 1/30 (2013.01); G01N 33/68 (2013.01); G16H 10/40 (2018.01); G16H 50/20 (2018.01); G16H 50/30 (2018.01);
Abstract

Provided is a method for quantifying Aβ in plasma by treating the plasma with MPP and/or TCEP, and a method for diagnosing, using the quantifying method, whether or not clinical cognitive deterioration and pathological Aβ accumulation occur. Through cut-off values of measured values measured by the method for quantifying Aβ according to the present subject matter, it is possible to identify normal, MCI and AD subjects and determine whether or not accumulation of Aβ in the brain occurs, and it is possible to predict progression to AD.

Find Patent Forward Citations

Loading…